GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sientra Inc (OTCPK:SIENQ) » Definitions » ROA %
中文

Sientra (Sientra) ROA % : -41.33% (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Sientra ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Sientra's annualized Net Income for the quarter that ended in Sep. 2023 was $-59.09 Mil. Sientra's average Total Assets over the quarter that ended in Sep. 2023 was $142.97 Mil. Therefore, Sientra's annualized ROA % for the quarter that ended in Sep. 2023 was -41.33%.

The historical rank and industry rank for Sientra's ROA % or its related term are showing as below:

SIENQ' s ROA % Range Over the Past 10 Years
Min: -63.42   Med: -37.01   Max: -6.05
Current: -38.38

During the past 11 years, Sientra's highest ROA % was -6.05%. The lowest was -63.42%. And the median was -37.01%.

SIENQ's ROA % is ranked worse than
77.23% of 865 companies
in the Medical Devices & Instruments industry
Industry Median: -1.64 vs SIENQ: -38.38

Sientra ROA % Historical Data

The historical data trend for Sientra's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sientra ROA % Chart

Sientra Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -63.42 -57.31 -48.18 -33.88 -40.13

Sientra Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.13 -53.07 -32.39 -25.35 -41.33

Competitive Comparison of Sientra's ROA %

For the Medical Devices subindustry, Sientra's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sientra's ROA % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sientra's ROA % distribution charts can be found below:

* The bar in red indicates where Sientra's ROA % falls into.



Sientra ROA % Calculation

Sientra's annualized ROA % for the fiscal year that ended in Dec. 2022 is calculated as:

ROA %=Net Income (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=-73.307/( (199.904+165.421)/ 2 )
=-73.307/182.6625
=-40.13 %

Sientra's annualized ROA % for the quarter that ended in Sep. 2023 is calculated as:

ROA %=Net Income (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=-59.092/( (145.999+139.933)/ 2 )
=-59.092/142.966
=-41.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2023) net income data. ROA % is displayed in the 30-year financial page.


Sientra  (OTCPK:SIENQ) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-59.092/142.966
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-59.092 / 78.176)*(78.176 / 142.966)
=Net Margin %*Asset Turnover
=-75.59 %*0.5468
=-41.33 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Sientra ROA % Related Terms

Thank you for viewing the detailed overview of Sientra's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sientra (Sientra) Business Description

Traded in Other Exchanges
Address
3333 Michelson Drive, Suite 650, Irvine, CA, USA, 92612
Sientra Inc is a part of the healthcare sector in the United States. Its business involves the provision of silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. Its operating segments are Breast Products and miraDry. The Breast Products segment focuses on sales of breast implants, tissue expanders and scar management products under the brands OPUS, AlloX2, Dermaspan, Softspan, and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System and bioTips. Geographically, the firm generates a majority of its revenue from the United States.
Executives
Alexander W. Casdin director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
Ronald Menezes director, officer: President and CEO 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Van Hove Caroline F. director 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Oliver Christian Bennett officer: General Counsel and VP 420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Andrew C Schmidt officer: Chief Financial Officer 1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Irina Erenburg director 420 S. FAIRVIEW AVENUE, SANTA BARBARA CA 93117
Nori Ebersole director C/O UROVANT SCIENCES, INC., 5151 CALIFORNIA AVENUE, SUITE 250, IRVINE CA 92617
Valerie J Miller officer: VP, Controller and Interim CFO
Paul Sean Little officer: Chief Financial Officer SIENTRA, INC., 420 SOUTH FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Jeffrey M Nugent director 1875 SOUTH GRANT STREET, SUITE 110, SAN MATEO CA 94402
Keith J Sullivan director C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
Timothy Haines director, 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Philippe Schaison director C/O ACTAVIS PLC MORRIS CORP CENTER III, 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054

Sientra (Sientra) Headlines

From GuruFocus

Q4 2018 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2021 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2019 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2020 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2022 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2019 Sientra Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024